4.5 Review

Unraveling the Mysteries of Endostatin

期刊

IUBMB LIFE
卷 61, 期 6, 页码 613-626

出版社

WILEY
DOI: 10.1002/iub.215

关键词

endostatin; clinical trials; zinc binding; folding criteria; receptor

向作者/读者索取更多资源

Endostatin, a 20-kDa C-terminal proteolytic fragment of collagen XVIII, is a specific endogenous angiogenesis inhibitor discovered more than a decade. The structure, stability,, and mechanism of actions of endostatin have been extensively investigated (luring the past 12 years, among which controversial reports remain unclarified. The in mysteries include the following: 11) Why, controversial efficacies were observed with endostatin regarding tumor inhibition? Particularly, why does an N-terminal modified endostatin show good clinical responses in China, whereas the clinical trials of the wild type endostatin were terminated at the early stage of phase II in the USA? 2) What is the contribution of zinc-binding to the stability and biological functions of endostatin? 3) Why does insoluble endostatin shrink tumors? 4) How to ensure that endostatin is correctly, refolded? 5) How does endostatin exert its biological functions? Recent progress regarding the biophysical properties, biological functions, signaling path-ways, and clinical trials of endostatin tire reviewed here. Surprising findings show that the integrity of the N-terminal sequence, the capability of zinc-binding, and the correct folding are three essential elements for assurance of structural stability and biological functions of endostatin. This review, provides clues to understand the mysteries of endostatin and its derivatives. (C) 2009 IUBMB IUBMB Life, 61(6): 613-626, 2009

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据